5-甲基-4-异恶唑羰酰氯 | 67305-24-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-甲基-4-异恶唑羰酰氯
• 中文别名: 5-甲基-4-异恶唑羰基氯
• 英文名称: 5-methylisoxazole-4-carbonyl chloride
• 英文别名: 5-methyl-4-isoxazole carbonyl chloride；5-methyl-4-isoxazolecarboxylic acid chloride；5-Methyl-4-isoxazolecarbonyl chloride；5-methyl-1,2-oxazole-4-carbonyl chloride
• CAS: 67305-24-2
• 化学式: C₅H₄ClNO₂
• mdl: MFCD03411599
• 分子量: 145.545
• InChiKey: ZKAQPVQEYCFRTK-UHFFFAOYSA-N

物化性质

• 沸点：
  78 °C
• 密度：
  1.345±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  43.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  C,Xi
• 海关编码：
  2934999090
• 包装等级：
  III
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P321,P363,P405,P501
• 危险品运输编号：
  3265
• 危险性描述：
  H314
• 储存条件：
  2-8°C

SDS

Name:	5-Methyl-4-isoxazolecarbonyl chloride Material Safety Data Sheet
Synonym:	None Known
CAS:	67305-24-2

Section 1 - Chemical Product MSDS Name:5-Methyl-4-isoxazolecarbonyl chloride Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
67305-24-2	5-Methyl-4-isoxazolecarbonyl chloride	97+%	unlisted

Hazard Symbols: C
Risk Phrases: 14 29 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Reacts violently with water. Contact with water liberates toxic gas.
Causes burns.Water-reactive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately. Do NOT allow victim to rub eyes or keep eyes closed.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Water Reactive. Material will react with water and may release a flammable and/or toxic gas.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide. DO NOT USE WATER! Contact professional fire-fighters immediately.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation. Do not expose spill to water.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not allow water to get into the container because of violent reaction. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Do not ingest or inhale. Use only in a chemical fume hood. Discard contaminated shoes. Keep from contact with moist air and steam.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Keep away from water. Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use explosion-proof ventilation equipment. Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower.
Exposure Limits CAS# 67305-24-2: Personal Protective Equipment Eyes: Wear chemical splash goggles and face shield.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Colourless
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 78 - 79 deg C @14mm Hg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C5H4ClNO2
Molecular Weight: 145.55

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures. Combines vigorously or explosively with water. Reacts with water to form hydrogen chloride, a toxic and corrosive gas.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong bases, water.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 67305-24-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
5-Methyl-4-isoxazolecarbonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, WATER-REACTIVE, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing Group: II
IMO
Shipping Name: CORROSIVE LIQUID, WATER-REACTIVE, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing Group: II
RID/ADR
Shipping Name: CORROSIVE LIQUID, WATER-REACTIVE, N.O.S.
Hazard Class: 8
UN Number: 3265
Packing group: II

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 14 Reacts violently with water.
R 29 Contact with water liberates toxic gas.
R 34 Causes burns.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 30 Never add water to this product.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 67305-24-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 67305-24-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 67305-24-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-甲基-4-异恶唑羰酰氯 在 铜 、 三乙胺 、 亚硝酸异戊酯 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 反应 8.0h， 生成 来氟米特
  参考文献：
  名称：

  铜促进的 Sandmeyer 三氟甲基化反应

  摘要：

  描述了芳香胺的铜促进的三氟甲基化反应。这种转化在温和条件下顺利进行，并且对许多合成相关的官能团表现出良好的耐受性。它为合成三氟甲基化芳烃和杂芳烃提供了一种替代方法。它也构成了桑德迈尔反应的一个新例子。

  DOI：

  10.1021/ja404217t
• 作为产物：
  描述：

  5-甲基-4-异噁唑甲酸乙酯 在 氯化亚砜 、 硫酸 、 N,N-二甲基甲酰胺 作用下， 以 二氯甲烷 、 水 为溶剂， 反应 32.0h， 生成 5-甲基-4-异恶唑羰酰氯
  参考文献：
  名称：

  新型来氟米特类似物的合成及体内抗纤维化活性

  摘要：

  合成了新型来氟米特类似物，并在体内针对硫代乙酰胺（TAA）诱导的大鼠肝纤维化进行了评估。与使用来氟米特治疗的动物相比，用新类似物治疗的所有动物均显示出提高的或相当的存活率。用化合物8d，8e，9和11治疗的动物显示出比来氟米特治疗的动物改善的肝脏参数。肝脏的组织病理学研究表明，化合物8a是活性最高的化合物，可将纤维化降低至最低水平，化合物8c，8e和11是纤维化评分为2-3的活性化合物，优于来氟米特。

  DOI：

  10.2174/1570180813666160630125624

文献信息

• MACROCYCLIC COMPOUNDS AND THEIR USE AS KINASE INHIBITORS
  申请人：Combs Andrew Paul

  公开号：US20090286778A1

  公开（公告）日：2009-11-19

  The present invention relates to macrocyclic compounds of Formula I: or pharmaceutically acceptable salts thereof or quaternary ammonium salts thereof wherein constituent members are provided hereinwith, as well as their compositions and methods of use, which are JAK/ALK inhibitors useful in the treatment of JAK/ALK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及以下化学式I的大环化合物： 或其药用可接受盐或季铵盐，其中所述成员在此提供，并且它们的组成物和使用方法，这些JAK/ALK抑制剂在治疗JAK/ALK相关疾病中有用，例如炎症和自身免疫性疾病以及癌症。
• Syntheses of 3-acetoacetylaminobenzo[b]furan derivatives having cysteinyl leukotriene 2 receptor antagonistic activity
  作者：Kumiko Ando、Eriko Tsuji、Yuko Ando、Noriko Kuwata、Jun-ichi Kunitomo、Masayuki Yamashita、Shunsaku Ohta、Shigekatsu Kohno、Yoshitaka Ohishi

  DOI：10.1039/b312682j

  日期：——

  Novel 3-acetoacetylaminobenzo[b]furan derivatives having a modified triene system at the 3-position were synthesized starting with 3-aminobenzo[b]furans. The enol isomers, 3-[(3-hydroxybut-2-enonyl)amino]benzo[b]furans (), of the 3-acetoacetylaminobenzo[b]furans were obtained as stable isomers owing to formation of a hydrogen bonding between the enol hydroxyl group and the amidocarbonyl group. The

  从3-氨基苯并[b]呋喃开始，合成了在3-位具有修饰的三烯系统的新型3-乙酰乙酰氨基苯并[b]呋喃衍生物。由于3-烯丙基乙酰氨基苯并[b]呋喃之间形成氢键，因此作为稳定异构体获得了3-乙酰基乙酰氨基苯并[b]呋喃的烯醇异构体3-[（3-羟基丁-2-烯丙基）氨基]苯并[b]呋喃。羟基和酰胺羰基。通过C-3侧链的C-2取代基的平面性表明烯醇化合物中存在改性的共轭三烯系统。评估了半胱氨酸白三烯1和2受体对这些化合物的拮抗活性。2-（4-氰基苯甲酰基或乙氧基羰基）-3-[（2-氰基-3-羟基丁-2-烯丙基）氨基]苯并[b]呋喃（，）具有中等活性。
• [EN] AU(III) COMPLEXES FOR [18F] TRIFLUOROMETHYLATION AND METHODS FOR PRODUCING THE SAME<br/>[FR] COMPLEXES AU(III) POUR TRIFLUOROMÉTHYLATION [18F] ET LEURS PROCÉDÉS DE PRODUCTION
  申请人：UNIV CALIFORNIA

  公开号：WO2018217637A1

  公开（公告）日：2018-11-29

  Au(III) complexes for [18F] trifluoromethylation and methods for producing the same are disclosed. A gold complex comprises Au(CF3)2LR, wherein L comprises a solubility supporting ligand and R comprises an organic substituent. The Au(III) complex can be used to prepare a positron emitting isotope that can be used as tracers for positron emitting tomography (PET) scans.

  揭示了用于[18F]三氟甲基化的Au(III)配合物以及生产这些配合物的方法。金配合物包括Au(CF3)2LR，其中L包括一种增溶性支持配体，R包括一个有机取代基。这种Au(III)配合物可用于制备可用作正电子发射断层扫描（PET扫描）示踪剂的正电子发射同位素。
• FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF
  申请人：Sakai Nozomu

  公开号：US20090137595A1

  公开（公告）日：2009-05-28

  The present invention provides a fused heterocyclic derivative having a potent kinase inhibitory activity and use thereof. A compound represented by the formula (I): wherein each symbol is as defined in the specification, except a particular compound, or a salt thereof, and a pharmaceutical agent containing the compound or a prodrug thereof, which is a kinase (VEGFR, VEGFR2, PDGFR, Raf) inhibitor, an angiogenesis inhibitor, an agent for the prophylaxis or treatment of cancer, a cancer growth inhibitor or a cancer metastasis suppressor.

  本发明提供了一种具有强大激酶抑制活性的融合杂环衍生物及其用途。 一种由以下式（I）表示的化合物： 其中除了特定化合物或其盐外，每个符号如规范中定义，以及含有该化合物或其前药的药用剂，该化合物是激酶（VEGFR、VEGFR2、PDGFR、Raf）抑制剂，血管生成抑制剂，用于癌症的预防或治疗的药剂，癌症生长抑制剂或癌症转移抑制剂。
• [EN] SPIROCYCLIC HAT INHIBITORS AND METHODS FOR THEIR USE<br/>[FR] INHIBITEURS DE HAT SPIROCYCLIQUES ET LEURS PROCÉDÉS D'UTILISATION
  申请人：ABBVIE INC

  公开号：WO2016044770A1

  公开（公告）日：2016-03-24

  Compounds having a structure of Formula (IX) or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2a, R2b, R3a, R3b, R4a, R4b, Q1----Q2, R6, R7, A, B, W, x, and y are as defined herein and are provided. Pharmaceutical compositions comprising such compounds and methods for treating various HAT-related conditions or diseases, including cancer, by administration of such compounds are also provided.

  具有式（IX）的结构或其立体异构体、互变异构体或药学上可接受的盐的化合物，其中R1、R2a、R2b、R3a、R3b、R4a、R4b、Q1----Q2、R6、R7、A、B、W、x和y如本文所定义，并提供。还提供了包括这些化合物的药物组合物和通过给予这些化合物治疗各种HAT相关疾病或疾病，包括癌症的方法。